![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Customvis | LSE:CUS | London | Ordinary Share | GB0033220350 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.93 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:2903T CustomVis plc 16 December 2003 Embargoed until 0700 16 December 2003 CustomVis plc ("CustomVis" or "the Group") AGM Statement At CustomVis's Annual General Meeting at 2pm today, Chairman Bill Colvin will give the following update: "As reported in our preliminary results statement on 2 October, the period since the Group's IPO in July 2003 has been one of significant advancement for the Group. "The funds raised at the IPO were inter alia to enable management to scale up the Group's production, sales and service capabilities. The Group has now largely completed its recruitment and training of additional skilled staff plus the acquisition of equipment and materials required to move closer to full scale production. Negotiations with distributors who will sell and service the systems have either been completed or are close to completion. "Production of machines is on track and we expect our first machine to be shipped to Europe before the end of December, with a further two to be dispatched in January 2004. All of the skilled and experienced individuals and resources that we require are now in place and CustomVis is well on track in terms of meeting our objectives for 2004 and beyond. "We will commence recording clinical data in 2004 and it is anticipated that the clinical data will be published and reported on at leading ophthalmic conferences during 2004, which will further enhance our reputation for achieving a very high standard of clinical outcome. "We continue to be prudent with our cash and our cash balances as at the end of November 2004 were #10.38 million. Our monthly cash spend is about #300,000 and is in accordance with our budgets. "The Group expects to announce interim results for the 6 months ended 31 December 2003 in March 2004." - Ends - Further information: CustomVis Simon Gordon, Managing Director 01382 738 545 Hugh Grant, Finance Director 01382 341 532 Weber Shandwick Square Mile Susan Ellis or Susanne Walker 0207 067 0700 This information is provided by RNS The company news service from the London Stock Exchange END AGMBIBDDXXBGGXU
1 Year Customvis Chart |
1 Month Customvis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions